摘要
目的探讨基质金属蛋白酶9(MMP9)、乙酰肝素酶(HPSE)和血管内皮生长因子C(VEGFC)蛋白表达在中老年人肺癌抗血管和抗淋巴管生成治疗中的意义。方法应用免疫组化SABC法检测MMP9、HPSE和VEGFC蛋白表达在65例肺癌组织中的表达,并与癌旁组织和正常肺组织对比,同时结合肺癌的临床病理学特征及预后进行分析。结果肺癌组织中MMP9、HPSE和VEGFC蛋白的阳性表达率明显高于正常肺组织和癌旁组织(P<005);不同类型和不同分化程度肺癌组织中MMP9、HPSE和VEGFC蛋白阳性表达率无显著性差异(P>005);Ⅲ期和Ⅳ期肺癌组织中MMP9、HPSE和VEGFC蛋白阳性表达率明显高于Ⅰ期和Ⅱ期(P<005);生存3年以下的肺癌组织中MMP9、HPSE和VEGFC蛋白阳性表达率明显高于生存3年以上者(P<005)。结论MMP9、HPSE蛋白表达在肺癌的生长、侵袭和转移以及血管生成中发挥重要作用;VEGFC是促进肺癌经淋巴转移的重要因素;肺癌的生长、侵袭和转移可能是MMP9、HPSE促血管生成和VEGFC促淋巴生成二者的协同作用;MMP9、HPSE和VEGFC蛋白可作为判断肺癌生物学行为和患者预后的一个参考指标;为人肺癌抗血管和抗淋巴管生成治疗的可行性提供了一定的实验依据。
Objective To investigate significance of metalloproteinases-9 (MMP-9), heparanase (HPSE) and vascular endothelial growth factor-C (VEGF-C) protein expression in antiangiogenic and antilymphatic therapy for lung cancer of middle and aged people. ~Methods The expression of MMP-9, HPSE and VEGF-C proteins in lung cancer tissues, adjacent tissues of cancer and normal tissues were detected and analyzed by immunohistochemical SABC method combining the clinic pathological characteristic and prognosis of lung cancer of 65 cases. Results The rate of expression of MMP-9, HPSE and VEGF-C protein in tumor tissues was significantly higher than that in adjacent tissues of cancer and normal tissues (P<0.05). It was showed that MMP-9, HPSE and VEGF-C protein expression did significantly not correlate with the type and grade of the tumor (P>0.05), but it correlated with the clinical stage and survival time of the patients significantly (P<0.05). Conclusions The over-expression of MMP-9 and HPSE protein is closely related to development, invasion, metastasis and angiogenesis of lung cancer. VEGF-C acts as a key factor in the facilitation of lymphatic metastasis in lung cancer. The cooperation of MMP-9, HPSE and VEGF-C perhaps participate in regulation of invasion and metastasis of lung cancer. The expression of ~MMP-9 , HPSE and VEGF-C protein may be used as an useful marker of judging the biological behavior and prognosis of lung cancer. This result provides important experimental basis for antiangiogenic and antilymphatic therapy for lung cancer.
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2005年第1期29-31,共3页
Chinese Journal of Gerontology